NEURAL
NEURAL
THERAPEUTICS
Neural Therapeutics Inc. is an ethnobotanical drug discovery/development company focused on developing products and conducting research with psychoactive plants, the first being a cactus commonly known as San Pedro (Echinopsis pachanoi) containing mescaline.
Neural Therapeutics Inc. is an ethnobotanical drug discovery/development company focused on developing products and conducting research with psychoactive plants, the first being a cactus commonly known as San Pedro (Echinopsis pachanoi) containing mescaline.
Neural Therapeutics Inc. aims to find where the historical use in traditional medicine has proven to be effective and capitalize on the opportunities that can be applied in today’s Nutraceutical and Pharmaceutical markets.
Neural Therapeutics Inc. aims to find where the historical use in traditional medicine has proven to be effective and capitalize on the opportunities that can be applied in today’s Nutraceutical and Pharmaceutical markets.
We believe that nearly six thousand years of indigenous experience provides an invaluable source of information that unlocks the key to the capabilities of the whole plant extract. We strive to honor native traditions and treat the San Pedro plant as a source of medicine that the nature has provided.
We believe that nearly six thousand years of indigenous experience provides an invaluable source of information that unlocks the key to the capabilities of the whole plant extract. We strive to honor native traditions and treat the San Pedro plant as a source of medicine that the nature has provided.
Mental health issues are at the forefront of our concern as we see a surge in conditions like anxiety, depression, and substance abuse. Naturally extracted Mescaline, accompanied by other compounds, has demonstrated significant advantages when compared to current pharmaceuticals. We believe that medical practitioners and therapists will need all “tools” possible.
We begin with a common R&D process that branches into two paths developing pharmaceuticals and nutraceuticals with the aim of utilizing the entire plant and creating zero waste.
We begin with a common R&D process that branches into two paths developing pharmaceuticals and nutraceuticals with the aim of utilizing the entire plant and creating zero waste.
Mr. Campbell is an executive leader with an international reputation in the US, Canada, and Czech Republic for his work in the fields of environmental science and pharmacology.
Dr. Dyck is a renowned scientist and professor with 30+ years of experience studying heart disease and pathogenesis of heart defects.
Dr. Narine has her PhD in Medical Genetics and is the former Vice President of Global Research & Medical Affairs at Aurora Cannabis Inc.
Mr. Durfy is currently a CEO and Director of High Fusion Inc. Over the past 30 years he has honed his executive experience in operations, investment management, and financial and business strategy.
Mr. McLelland started his business career as an accountant at Ernst & Young LLP before moving into mid-market investment banking.
Mr. Wilson’s past leadership in corporate finance, investor relations, governance, financial and regulatory reporting, and mergers and acquisitions has led him to his current role as the Chief Financial Officer of High Fusion Inc.
David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science at the Imperial College London.
Dr. Wieman has 20+ years of psychiatric experience and is a leader in Indigenous health and medical education.
Dr. Fu is one of the few Board-certified Nuclear Pharmacists (BCNP) in the State of Nevada and has extensive experience with mycology.
Please provide your email to get a download link for our corporate deck.
|
May 17, 2023 / News Releases
February 2, 2023 / News Releases
January 9, 2023 / News Releases
November 4, 2022 / News Releases
October 14, 2022 / News Releases